{"id":"menatetrenone","rwe":[{"pmid":"41657105","year":"2026","title":"MK4 Repositioning for IAHSP: Overcoming In Vivo Data Gaps through In Silico Refinement and In Vitro Validation.","finding":"","journal":"ACS chemical neuroscience","studyType":"Clinical Study"},{"pmid":"41537160","year":"2026","title":"Hereditary spastic paraplegia: from decades of therapy to future innovations.","finding":"","journal":"Therapeutic advances in neurological disorders","studyType":"Clinical Study"},{"pmid":"40272187","year":"2025","title":"Integrated microbiology and metabolomics analysis reveal the fermentation process and the flavor development in cigar tobacco leaf.","finding":"","journal":"Microbiology spectrum","studyType":"Clinical Study"},{"pmid":"29999981","year":"2006","title":"Vitamin K.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"39898865","year":"2025","title":"Exploring Menatetrenone: Origin, Chemistry, Therapies and Delivery.","finding":"","journal":"Journal of the American Nutrition Association","studyType":"Clinical Study"}],"tags":[{"label":"menatetrenone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-synuclein","category":"target"},{"label":"SNCA","category":"gene"},{"label":"M05BX08","category":"atc"},{"label":"Active","category":"status"},{"label":"Hemorrhagic disease of the newborn due to vitamin K deficiency","category":"indication"},{"label":"Antifibrinolytic Agents","category":"pharmacology"},{"label":"Coagulants","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Hemostatics","category":"pharmacology"},{"label":"Micronutrients","category":"pharmacology"},{"label":"Vitamins","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":89.189,"date":"","count":40,"signal":"Cerebral haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=89)"},{"llr":79.041,"date":"","count":34,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=79)"},{"llr":72.919,"date":"","count":37,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=73)"},{"llr":50.061,"date":"","count":23,"signal":"Disseminated intravascular coagulation","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=50)"},{"llr":49.279,"date":"","count":43,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=49)"},{"llr":41.831,"date":"","count":13,"signal":"Brain herniation","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=42)"},{"llr":37.519,"date":"","count":70,"signal":"Pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 70 times (LLR=38)"},{"llr":33.382,"date":"","count":19,"signal":"Altered state of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=33)"},{"llr":32.562,"date":"","count":11,"signal":"Embolic stroke","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=33)"},{"llr":32.191,"date":"","count":10,"signal":"Intraventricular haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=32)"},{"llr":30.92,"date":"","count":30,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=31)"},{"llr":30.587,"date":"","count":9,"signal":"Upper respiratory tract inflammation","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=31)"},{"llr":30.409,"date":"","count":5,"signal":"Posthaemorrhagic hydrocephalus","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=30)"},{"llr":28.987,"date":"","count":20,"signal":"Pneumonia aspiration","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=29)"},{"llr":28.9,"date":"","count":14,"signal":"Brain oedema","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=29)"}],"commonSideEffects":[{"effect":"Cerebral haemorrhage","drugRate":"LLR 89","severity":"common"},{"effect":"Cerebral infarction","drugRate":"LLR 79","severity":"common"},{"effect":"Hepatic function abnormal","drugRate":"LLR 73","severity":"common"},{"effect":"Disseminated intravascular coagulation","drugRate":"LLR 50","severity":"common"},{"effect":"Platelet count decreased","drugRate":"LLR 49","severity":"common"},{"effect":"Brain herniation","drugRate":"LLR 42","severity":"common"},{"effect":"Pneumonia","drugRate":"LLR 38","severity":"common"},{"effect":"Altered state of consciousness","drugRate":"LLR 33","severity":"common"},{"effect":"Embolic stroke","drugRate":"LLR 33","severity":"common"},{"effect":"Intraventricular haemorrhage","drugRate":"LLR 32","severity":"common"},{"effect":"Renal impairment","drugRate":"LLR 31","severity":"common"},{"effect":"Upper respiratory tract inflammation","drugRate":"LLR 31","severity":"common"},{"effect":"Posthaemorrhagic hydrocephalus","drugRate":"LLR 30","severity":"common"},{"effect":"Brain oedema","drugRate":"LLR 29","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"vitamin mk 4","offLabel":[],"synonyms":["menatetrenone","Menaquinone 4","Vitamin MK 4","vitamin k2"],"timeline":[],"approvals":[],"brandName":"Vitamin Mk 4","ecosystem":[{"indication":"Hemorrhagic disease of the newborn due to vitamin K deficiency","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Alpha-synuclein","targets":[{"gene":"SNCA","source":"DrugCentral","target":"Alpha-synuclein","protein":"Alpha-synuclein"}],"modality":"Small Molecule","drugClass":"menatetrenone","explanation":"Imagine your blood as a liquid that needs to be able to clot to stop bleeding when you get hurt. Vitamin K helps your body make the proteins that allow your blood to clot. Menatetrenone is a synthetic version of vitamin K that can help your body make these proteins and stop bleeding.","oneSentence":"Menatetrenone works by acting as a vitamin K analog to promote blood clotting.","technicalDetail":"Menatetrenone functions as a vitamin K analog by binding to the vitamin K-dependent carboxylase enzyme, facilitating the gamma-carboxylation of glutamate residues on target proteins, including clotting factors II, VII, IX, and X, thereby promoting blood coagulation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1685","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MENATETRENONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MENATETRENONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:06:23.190851","biosimilars":[],"competitors":[{"drugName":"aluminium chlorohydrate","drugSlug":"aluminium-chlorohydrate","fdaApproval":"","relationship":"same-class"},{"drugName":"denosumab","drugSlug":"denosumab","fdaApproval":"2010-06-01","relationship":"same-class"},{"drugName":"burosumab","drugSlug":"burosumab","fdaApproval":"2018-04-17","relationship":"same-class"},{"drugName":"romosozumab","drugSlug":"romosozumab","fdaApproval":"2019-04-09","relationship":"same-class"},{"drugName":"vosoritide","drugSlug":"vosoritide","fdaApproval":"2021-11-19","patentExpiry":"May 20, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"colecalciferol","drugSlug":"colecalciferol","fdaApproval":"2000-05-18","relationship":"same-class"}],"genericName":"menatetrenone","indications":{"approved":[{"name":"Hemorrhagic disease of the newborn due to vitamin K deficiency","source":"DrugCentral","snomedId":12546009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"aluminium-chlorohydrate","brandName":"aluminium chlorohydrate","genericName":"aluminium chlorohydrate","approvalYear":"","relationship":"same-class"},{"drugId":"denosumab","brandName":"denosumab","genericName":"denosumab","approvalYear":"2010","relationship":"same-class"},{"drugId":"burosumab","brandName":"burosumab","genericName":"burosumab","approvalYear":"2018","relationship":"same-class"},{"drugId":"romosozumab","brandName":"romosozumab","genericName":"romosozumab","approvalYear":"2019","relationship":"same-class"},{"drugId":"vosoritide","brandName":"vosoritide","genericName":"vosoritide","approvalYear":"2021","relationship":"same-class"},{"drugId":"colecalciferol","brandName":"colecalciferol","genericName":"colecalciferol","approvalYear":"2000","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07041645","phase":"NA","title":"Bioavailability of Different Vitamin K Vitamers Studied Using 13C-labelled Vitamin K Vitamers","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2025-07-01","conditions":["Bioavailability of Vitamin K"],"enrollment":20,"completionDate":"2031-06-30"},{"nctId":"NCT05995522","phase":"NA","title":"Effect of Vitamin K2 Over Osteocalcin, Leptin, Cytokines, and Cardiovascular Risk in Young Adults With Overweight and Obesity","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2023-09-01","conditions":["Overweight and Obesity","Cardiometabolic Risk Factors"],"enrollment":51,"completionDate":"2023-12-31"},{"nctId":"NCT04719572","phase":"NA","title":"Intervention Study of Drugs in Patients Osteopenia and Osteoporosis","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03","conditions":["Osteoporosis","Osteopenia, Osteoporosis"],"enrollment":180,"completionDate":"2023-01"},{"nctId":"NCT01232647","phase":"PHASE2,PHASE3","title":"Vitamin K as Additive Treatment in Osteoporosis","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2015-04","conditions":["Post-menopausal Osteoporosis"],"enrollment":105,"completionDate":"2020-03-31"},{"nctId":"NCT00548509","phase":"PHASE4","title":"The Effect of Vitamin K2 on Bone Turnover","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2002-02-01","conditions":["Osteoporosis"],"enrollment":131,"completionDate":"2013-01"},{"nctId":"NCT00165698","phase":"PHASE3","title":"Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2005-05","conditions":["Postmenopausal Osteoporosis"],"enrollment":240,"completionDate":"2007-07"},{"nctId":"NCT01143831","phase":"NA","title":"Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation","status":"COMPLETED","sponsor":"Stephan Moll, MD","startDate":"2009-11","conditions":["Thrombosis"],"enrollment":8,"completionDate":"2012-03"},{"nctId":"NCT00960973","phase":"PHASE4","title":"The Effect of Vitamin K Supplementation on Glucose Metabolism","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-09","conditions":["Diabetes","Prediabetic State"],"enrollment":42,"completionDate":"2010-12"},{"nctId":"NCT00165633","phase":"PHASE2,PHASE3","title":"A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"Eisai Limited","startDate":"2004-03","conditions":["Hepatocellular Carcinoma"],"enrollment":540,"completionDate":"2007-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"337527","NDDF":"012756","UNII":"27Y876D139","CHEBI":"CHEBI:16374","INN_ID":"3292","RXNORM":"29495","UMLSCUI":"C0065936","ChEMBL_ID":"CHEMBL259223","KEGG_DRUG":"D00100","DRUGBANK_ID":"DB12148","PDB_CHEM_ID":" 1L3","PUBCHEM_CID":"5282367","SNOMEDCT_US":"22606007","IUPHAR_LIGAND_ID":"2771","MESH_DESCRIPTOR_UI":"D024482","MESH_SUPPLEMENTAL_RECORD_UI":"C030814"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"23%"},"publicationCount":190,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"M05BX08","allCodes":["M05BX08"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 18","pmid":"41657105","title":"MK4 Repositioning for IAHSP: Overcoming In Vivo Data Gaps through In Silico Refinement and In Vitro Validation.","journal":"ACS chemical neuroscience"},{"date":"2026","pmid":"41537160","title":"Hereditary spastic paraplegia: from decades of therapy to future innovations.","journal":"Therapeutic advances in neurological disorders"},{"date":"2025 Jun 3","pmid":"40272187","title":"Integrated microbiology and metabolomics analysis reveal the fermentation process and the flavor development in cigar tobacco leaf.","journal":"Microbiology spectrum"},{"date":"2006","pmid":"29999981","title":"Vitamin K.","journal":""},{"date":"2025 Aug","pmid":"39898865","title":"Exploring Menatetrenone: Origin, Chemistry, Therapies and Delivery.","journal":"Journal of the American Nutrition Association"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vitamin Mk 4, also known as menatetrenone, is a small molecule drug in the menatetrenone class that targets alpha-synuclein. It is currently used to treat hemorrhagic disease of the newborn due to vitamin K deficiency. The commercial status of Vitamin Mk 4 is unclear, as it is not known whether it is patented or generic, and it is not approved by the FDA for any indications other than its original use. The bioavailability of Vitamin Mk 4 is 23%, but its half-life is unknown. As a result, its use is limited to its original approved indication.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}